Adenosine as a neuroprotectant: therapeutic perspectives

References

• Siesjo BK. Pathophysiology and treatment of focal cerebral ischaemia. Part I. Pathophysiology. j Neurosurg. 77,169–184 (1992).
   PubMed Web of Science ®Google Scholar
• •• This paper provides a good introduction to stroke injury.
   Google Scholar
• Fredholm BB, bzerman AP, Jacobson KA, Klotz JN, Linden J. International Union of Pharmacology XXV. Nomenclature and Classification of Adenosine Receptors. Pharmacol. Rev 534,527–552 (2001).
   Google Scholar
• •The most recent synopsis of information on adenosine receptors.
   Google Scholar
• Rudolphi KA, Schubert P Purinergic interventions in traumatic and ischemic injury. In: Novel Therapies for CNS Injuries: Rationales and Results Peterson PL, Phillis JW (Eds.), Academic Press, Boca Raton, 327–346 (1996).
   Google Scholar
• Haas HL, Selbach 0. Functions of neuronal adenosine receptors. Naunyn-Schmiedebergs Arch. Pharmac. 362,375-381 (2000).
   Google Scholar
• Dunwiddie TV, Diao L, Kim HO, Jiang JL, Jacobson KA. Activation of hippocampal adenosine A3 receptors produces a desensitization of A1 receptor-mediated responses in rat hippocampus. j Neurosci. 17,607-614 (1997).
   Google Scholar
• Ali H, Cunha-Melo JR, Saul WF, Beaven MA. Activation of phospholipase C via adenosine receptor provides synergistic signals for secretion in antigen-stimulated RBL-2H3 cells: evidence for a novel adenosine receptor. j Biol. Chem. 265, 745–753 (1990).
   Google Scholar
• Rosin DL, Robeva A, Woodard RL, Guyenet PG, Linden J. Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system. J. Comp. Neurol. 401,163-186 (1998).
   Google Scholar
• Moreau JL, Huber G. Central adenosine A(2A) receptors: an overview. Brain Res. Rev 31,65–82 (1999).
   Google Scholar
• ••A nice review on the role of centraladenosine receptors.
   Google Scholar
• Dixon AK, Gubitz AK, Sirinathsinghji DJS, Richardson PJ, Freeman TC. Tissue distribution of adenosine receptor mRNAs in the rat. Br. Pharmacol. 118,1461–1468 (1996).
   PubMed Web of Science ®Google Scholar
• Schiffmann SN, Libert F, Vassart G, Vanderhaeghen JJ. Distribution of adenosine A2 receptor mRNA in the human brain. Neurosci. Lett. 130,177-181 (1991).
   Google Scholar
• El Yacoubi M, Ledent C, Parmentier M, Ongini E, Costentin J, Vaugeois JM. In vivo labeling of the adenosine A2A receptor in mouse brain using the selective antagonist [H3] SCH-58261. Eur: Neurosci. 14(9), 1567–1570 (2001).
   Google Scholar
• Phillis JVV. Adenosine A2A receptor ligands: effects on neuronal excitability. Drug Develop. Res. 52,331-336 (2001).
   Google Scholar
• Lopes LV, Cunha RA, Ribeiro JA. Cross talk between A1 and A2A adenosine receptors in the hippocampus and cortex of young adult and old rats. j Neurophysiol. 82,3196-3203 (1999).
   Google Scholar
• Mayfield RD, Larson G, Orana RA, Zahniser NR. Opposing actions of adenosine A2A and dopamine D2 receptor activation on GABA release in the basal ganglia: evidence for an A2A/D2 receptor interaction in globus pallidus. Synapse 22, 132–138 (1996).
   PubMedGoogle Scholar
• Cunha RA, Ribeiro JA. Purinergic modulation of [3H] GABA release from rat hippocampal nerve terminals. Neuropharmacology 39,1156–1167 (2000).
   PubMed Web of Science ®Google Scholar
• Thomas T, Spyer KM. A novel influence of adenosine on ongoing activity in rat rostral ventrolateral medulla. Neuroscience 88(4), 1213–1223 (1999).
   PubMedGoogle Scholar
• Phillis JW. Adenosine in the control of the cerebral circulation. Cerebrovasc. Brain Metabol. Rev 1,26–54 (1989).
   PubMedGoogle Scholar
• Feoktistov I, Biaggioni I. Adenosine A2B receptors. Pharmacol. Rev 49,381–402 (1997).
   Google Scholar
• De Mendonca A, Sebastido AM, Ribeiro JA. Adenosine: does it have a neuroprotective role after all? Brain Res. Rev 33,258–274 (2000).
   Google Scholar
• •An excellent summary of in vitro and in vivo neuroprotective effects of adenosine.
   Google Scholar
• Evans MC, Swan JH, Meldrum BS. An adenosine analogue, 2-chloroadenosine, protects against long-term development of ischaemic cell loss in the rat hippocampus. Neurosci. Lett. 83,287-292 (1987).
   Google Scholar
• Von Lubitz DKJE. Adenosine and cerebral ischaemia: therapeutic future or death of a brave concept? Eur. j Pharmacol. 365,9–25 (1999).
   Google Scholar
• •Summarizes the extensive studies on adenosine receptor activation and neuroprotection by this group.
   Google Scholar
• Knutsen LJ, Lau J, Petersen H et al. N- substituted adenosines as novel neuroprotective A(1) agonists with diminished hypotensive effects. J. Med. Chem. 43,3463-3477 (1999).
   Google Scholar
• Johansson B, Halloner L, Dunwiddie TV et al. Hyperalgesia, anxiety and decreased hypoxic neuroprotection in mice lacking the adenosine A1 receptor. Proc. Nat. Acad. Sci. USA 98,9407–9412 (2001).
   Google Scholar
• Phillis JVV. The effects of selective A1 and A2A adenosine receptor antagonists on cerebral ischemic injury in the gerbil. Brain Res. 705,79–84 (1995).
   PubMed Web of Science ®Google Scholar
• ••A pivotal study drawing attention to deleterious neural effects of A2A receptor activation.
   Google Scholar
• Monopoli A, Lozza G, Forlani A, Manavelli A, Ongini E. Blockade of adenosine A2A receptors by SCH58261 results in neuroprotective effects in cerebral ischaemia in rats. Neuromport9, 3955–3959 (1998).
   Google Scholar
• O'Regan MH, Simpson RE, Perkins LM, Phillis JVV. The selective A2 adenosine agonist CGS 21680 enhances excitatory transmitter amino acid release from the ischemic rat cerebral cortex. Neurosci. Lett. 138,169-172 (1992).
   Google Scholar
• Chen J-F, Huang Z, Ma J et al. A2A adenosine receptor deficiency attenuates brain injury induced by transient focal ischaemia in mice. j Neurosci. 19,9192–9200 (1999).
   PubMed Web of Science ®Google Scholar
• Von Lubitz DK, Simpson KL, Lin RC. Right thing at a wrong time? Adenosine A3 receptors and cerebroprotection in stroke. Ann. NY Acad. Sci. 939,85-96 (2001).
   Google Scholar
• Cerniway RJ, Yang Z, Jacobson MA, Linden J, Matherne GP Targeted deletion of A(3) adenosine receptors improves tolerance to ischaemia-reperfusion injury in mouse myocardium. Am. j Physiol. 281, H1751—H1758 (2001).
   Google Scholar
• Palmer TM, Benovic JL, Stiles GL. Molecular basis for subtype-specific desensitization of inhibitory adenosine receptors. Analysis of a chimeric A1-A3 adenosine receptor. J. Biol. Chem. 271, 15272–15278 (1996).
   Google Scholar
• Mullane K. Acadesine: the prototype adenosine regulating agent for reducing myocardial ischemic injury. Cardiovasc. Res. 27,43–47 (1993).
   PubMedGoogle Scholar
• Parkinson FE, Zhang YW, Shepel PN, Greenway SC, Peeling J, Geiger JD. Effects of nitrobenzylthioinosine on neuronal injury, adenosine levels and adenosine receptor activity in rat forebrain ischaemia. Neurochem. 75, 795–802 (2000).
   PubMed Web of Science ®Google Scholar
• Turcani P, Tureani M. Effect of propentofylline on cerebral blood flow in a gerbil focal cerebral ischaemia. j Neurol. Sci. 183, 57–60 (2001).
   PubMedGoogle Scholar
• Johnson MP, McCarty DR, Chmielewski PA. Temporal dependent neuroprotection with propentofylline (HWA 285) in a temporary focal ischaemia model. Eur. Pharmacol. 346, 151–157 (1998).
   Google Scholar
• Forbes CD. European stroke prevention study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stoke. Int.j Clin. Pract. 5,205-208 (1997).
   Google Scholar
• Phillis JVV. Adenosine in cerebral ischemic injury: both friend and foe. In: The Role of Adenosine in the Nervous System. Okada Y (Ed.), Elsevier Science By. Amsterdam, The Netherlands, 41–49 (1997).
   Google Scholar
• Gidday JM, Fitzgibbons JC, Shah AR, Kraujalis MJ, Park TS. Reduction in cerebral ischemic injury in the newborn rat by potentiation of endogenous adenosine. Pedian: Res. 38, 306–311 (1995).
   PubMedGoogle Scholar
• Delaney SM, Sutherland GR, Peeling J, Geiger JD. Failure of 2-deoxycoformycin to protect against transient forebrain ischaemia in rat. Neurosci. Lett. 149, 31–34 (1993).
   Google Scholar
• Palmer C, Towfighi J, Roberts RL, Heitjan DF. Allopurinol administered after inducing hypoxia-ischaemia reduces brain injury in 7 day old rats. Pediatr. Res. 33, 405–411 (1993).
   Google Scholar
• O'Regan MH, Smith-Barbour M, Perkins LM, Cao X, Phillis JVV. The effect of amflutizole, a xanthine oxidase inhibitor, on ischaemia-evoked purine release and free radical formation in the rat cerebral cortex. Neuropharmacol. 33, 1197–1201 (1994).
   PubMedGoogle Scholar
• Phillis JVV, Perkins LM, Smith-Barbour M, O'Regan MH. Oxypurinol-enhanced post-ischemic recovery of the rat brain involves preservation of adenine nucleotides. Neurochem. 64, 2177–2184 (1995).
   Google Scholar
• Phillis JVV, Smith-Barbour M. The adenosine kinase inhibitor, 5- iodotubercidin, is not protective against cerebral ischemic injury in the gerbil. Life Sci. 53, 497–502 (1993).
   PubMed Web of Science ®Google Scholar
• Miller LP, Jelovich LA, Yao L, Dare J, Ugarkar B, Foster AC. Pre- and peristroke treatment with the adenosine kinase inhibitor, 5'-deoxyiodotubercidin, significantly reduces infarct volume after temporary occlusion of the middle cerebral artery in rats. Neurosci. Lett. 220, 73–76 (1996).
   Google Scholar
• Jiang N, Kowaluk EA, Lee C-H, Mazdiyasni H, Chopp M. Adenosine kinase inhibition protects brain against transient focal ischaemia in rats. Eur. Pharmacol. 320, 131–137 (1997).
   Google Scholar
• Tatlisumak T, Takano K, Carano RA, Miller LP, Foster AC, Fisher M. Delayed treatment with an adenosine kinase inhibitor, GP 683, attenuates infarct size in rats with temporary middle cerebral artery occlusion. Stroke 29, 1952–1958 (1998).
   PubMed Web of Science ®Google Scholar
• Cao X, Phillis JW. Adenosine A1 receptor enhancer, PD 81,723 and cerebral ischaemia/reperfusion injury in the gerbil. Gen. Pharmacol. 26, 1545–1548 (1995).
   Google Scholar
• Halle JN, Kasper CE, Gidday JM, Koos BJ. Enhancing adenosine A1 receptor binding reduces hypoxic-ischemic brain injury in newborn rats. Brain Res. 759, 309–312 (1997).
   PubMed Web of Science ®Google Scholar
• Mudumbi RV, Montamat SC, Bruns RE, Vestal RE. Cardiac functional responses to adenosine by PD 81,723, an allosteric enhancer of the adenosine A1 receptor. Am.j Physiol. 264, H1017—H1022 (1993).
   Google Scholar
• Baraldi PG, Zaid AN, Lampronti I et al. Synthesis and biological effects of a new series of 2-amino-3-benzoylthiophenes as allosteric enhancers of Al-adenosine receptors. Bioorg. Med. Chem. Lett. 10, 1953–1957 (2000).
   Google Scholar
• Zhao ZQ, Williams MW, Sato H et al. Acadesine reduces myocardial infarct size by an adenosine mediated mechanism. Cardiovasc. Res. 29, 495–505 (1995).
   PubMedGoogle Scholar
• Walter GA, Phillis JVV. 5-Aminoimidazole- 4-carboxamide riboside administration and purine release from the hypoxic/ hypotensive rat cerebral cortex. Neurochem. Int. 15, 485–491 (1989).
   Google Scholar
• Headrick JP, Bendall MR, Faden Al, Vink R. Dissociation of adenosine levels from bioenergetic state in experimental brain trauma: potential in secondary injury. Cereb. Blood Flow Metabol. 14, 853–861 (1994).
   PubMed Web of Science ®Google Scholar
• Mitchell FL, Frisella WA, Brooker RW, Yoon K-W Attenuation of traumatic cell death by an adenosine A1 agonist in hippocampal cells. Neurosurgery 36, 1003–1007 (1995).
   PubMedGoogle Scholar
• Robertson CL, Hendrich KS, Kochanek PM et al. Assessment of 2-chloroadenosine treatment after experimental traumatic brain injury using arterial spin-labeled MRI: a preliminary report. Acta Neurochir. Suppl. 76, 187–189 (2000).
   Google Scholar
• Golding EM, Robertson CS, Bryan RM. The consequences of traumatic brain injury on cerebral blood flow and autoregulation: a review. Clin. Exp. Hypertens. 21, 299–332 (1999).
   Google Scholar
• Choi DW Glutamate neurotoxicity and diseases of the central nervous system. Neuron 1, 623–634 (1988).
   Google Scholar
• •One of the first reports suggesting the involvement of glutamate excitotoxicity in neurodegenerative disorders.
   Google Scholar
• Lipton SA. Neuronal injury associated with HIV-1: approaches to treatment. Ann. Rev Pharmacol. 38, 159–177 (1998).
   Google Scholar
• Ludolph AC, Meyer T, Riepe MW The role of excitotoxicity in ALS - what is the evidence?' Neurol. 247(1),1/7-1/16 (2000).
   Google Scholar
• Danbolt NC. Glutamate uptake. Prog. Neurobiol. 65,1–105 (2001).
   PubMed Web of Science ®Google Scholar
• ••Excellent recent review on glutamatetransporters and glutamate-evoked neural injury.
   Google Scholar
• Glass M, Dragunow M. Neurochemical and morphological changes associated with human epilepsy. Brain Res. Rev 21, 29–41 (1995).
   PubMedGoogle Scholar
• •This review provides a nice summary of the potential role of adenosine as an anti-epileptic agent.
   Google Scholar
• Adami M, Bertorelli R, Ferri N, Foddi E, Ongini E. Effects of repeated administration of selective A1 and A2A receptor agonists on pentylenetetrazol-induced convulsions in the rat. Eur. Pharmacol. 294, 383–389 (1995).
   Google Scholar
• De Sarro G, De Sarro A, Di Paola ED, Bertorelli R. Effects of adenosine receptor agonists and antagonists on audiogenic seizure-sensible DBA/2 mice. Eur. Pharmacol. 371, 137–145 (1999).
   Google Scholar
• Ferrarese C, Aliprandi A, Tremolizzo L et al. Increased glutamate in CSF and plasma of patients with HIV dementia. Neurology57, 671–675 (2001).
   PubMed Web of Science ®Google Scholar
• Rothstein JD, Van Kammen M, Levey Al, Martin LJ, Kuncl RW. Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral sclerosis. Ann. NeuroL 38, 73–84 (1995).
   Google Scholar
• Trotti D, Aoki M, Pasinelli P et al Amyotrophic lateral sclerosis-linked glutamate transporter mutant has impaired glutamate clearance capacity. j Biol. Chem. 276, 576–582 (2001).
   PubMed Web of Science ®Google Scholar
• Spreux-Varoquaux 0, Bensimon G, Lacomblez L et al. Glutamate levels in cerebrospinal fluid in amyotrophic lateral sclerosis: a reappraisal using a new HPLC method with coulometric detection in a large cohort of patients. j NeuroL ScL 193, 73–78 (2002).
   Google Scholar
• Sieradzan KA, Mann DM. The selective vulnerability of nerve cells in Huntington's disease. NeuropathoL AppL NeurobioL 27, 1–21 (2001).
   PubMed Web of Science ®Google Scholar
• Zeron MM, Chen N, Moshaver A et al. Mutant huntingtin enhances excitotoxic cell death. MoL Cell. Neurosci. 17,41–53 (2001).
   PubMedGoogle Scholar
• Ho LW, Carmichael J, Swartz J, Wyttenbach A, Rankin J, Rubinsztein DC. The molecular biology of Huntington's disease. PsychoL Med. 31, 3–14 (2001).
   PubMedGoogle Scholar
• Alexi T, Borlongan CV, Faull RU et al. Neuroprotective strategies for basal ganglia degeneration: Parkinson's and Huntington's disPases. Rog. Neurobiol 60,409–470 (2000).
   Google Scholar
• Mattson MP, Pedersen WA, Duan WW, Culmsee C, Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer's and Parkinson's diseases. Ann. NY Acad. Sci. USA 893, 154–175 (1999).
   Google Scholar
• Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 52, 1673–1677 (1999).
   PubMed Web of Science ®Google Scholar
• Kanda T, Jackson MJ, Smith LA et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann NeuroL 43, 507–513 (1998).
   PubMed Web of Science ®Google Scholar
• Ongini E, Monopoli A, Impagnatiello F, Fredduzzi S, Schwarzschild M, Chen J-E Dual actions of A2A adenosine receptor antagonists on motor dysfunction and neurodegenerative processes. Drug DeveL Res. 52, 379–386 (2001).
   Web of Science ®Google Scholar
• Montesinos C, Cronstein BN. Role of P1 receptors in inflammation. In: Handbook of Experimental Pharmacology - Purinergic and Pyrimidinergk Neurotransmission (Volume 151), Part II Abbrachio MP, Williams M (Eds.), Springer-Verlag, Berlin, Germany, 303–321 (2001).
   Google Scholar
• ••An excellent review of the role ofadenosine receptors on inflammation.
   Google Scholar
• Linden J. Molecular approach to adenosine receptors: Receptor mediated mechanisms of tissue protection. Ann. Rev PharmacoL ToxicoL 41, 775–787 (2001).
   PubMedGoogle Scholar
• Ohta A, Sitkovsky M. Role of G-protein coupled adenosine receptors in downregulation of inflammation and protection from tissue damage. Nature 414, 916–920 (2001).
   PubMed Web of Science ®Google Scholar
• Sawynok J. Adenosine receptor activation and nociception. Eur. j PharmacoL 347, 1–11 (1998).
   PubMed Web of Science ®Google Scholar
• ••A comprehensive account of adenosine receptor activation and pain.
   Google Scholar
• Kowaluk EA, Jarvis ME Therapeutic potential of adenosine kinase inhibitors. Expert Opin. Investig. Drugs 9, 551–564 (2000).
   PubMed Web of Science ®Google Scholar
• •Provides a good review on the potential therapeutic uses of adenosine kinase inhibitors.
   Google Scholar
• McGaraughty S, Chu KL, Wismer CT et al. Effects of A-134974, a novel adenosine kinase inhibitor, on carrageenan-induced inflammatory hyperalgesia and locomotor activity in rats: evaluation of the sites of action. J. PharmacoL Exp. Ther. 296, 501–509 (2001).
   Google Scholar
• Boyle DL, Kowaluk EA, Jarvis MF et al. Anti-inflammatory effects of ABT-702, a novel non-nucleoside adenosine kinase inhibitor, in rat adjuvant arthritis. j PharmacoL Exp. Ther. 296, 495–500 (2001).
   Google Scholar